WRIB 2023 White Paper Defines Bioanalysis Priorities Across Assays and Regulation
The 17th Workshop on Recent Issues in Bioanalysis brought more than 1,000 participants to Orlando in June 2023, drawing together professionals from pharma, biotech, CROs, and multiple regulatory agencies. The resulting 2023 White Paper on Recent Issues in Bioanalysis captures the practical recommendations that emerged from that week of discussion, with this first publication covering mass spectrometry assays, regulated bioanalysis and biomarker validation, plus the regulatory inputs that shaped the meeting’s scientific direction.
The white paper is not a clinical trial report, but it carries direct operational weight for how bioanalytical data are generated, defended, and submitted. In a field where assay performance can alter exposure estimates, biomarker interpretation, and the credibility of translational programs, workshop consensus functions as a working manual for method development and regulatory communication. The document reflects a broad international exchange centered on scientific rigor, quality systems, and the realities of regulated bioanalysis across small molecules and emerging therapeutic platforms.
A single week was set aside for the meeting to allow detailed coverage of biomarker bioanalysis, immunogenicity, gene therapy, cell therapy, and vaccines. The program also included special sessions on EU IVDR 2017/746 implementation and on US FDA/OSIS remote regulatory assessments, two subjects that have moved from administrative detail to day-to-day operational consequence for laboratories and sponsors. For many groups, these issues now affect how samples are handled, how studies are audited, and how evidence is assembled for regulatory review.
Mass Spectrometry and Chromatography Remain the Backbone of Regulated Bioanalysis
Mass spectrometry continues to anchor much of modern regulated bioanalysis because it can offer sensitivity, selectivity, and multiplexing capacity that other platforms cannot easily match. The workshop recommendations collected in this white paper focus on the latest developments in assay design, chromatography, sample preparation, and the practical solutions needed when matrices are complex and analytes are unstable, low-abundance, or structurally challenging.
The emphasis on sample preparation is especially important. Pre-analytical handling is often where analytical integrity is won or lost, particularly when dealing with biologics, circulating biomarkers, or small molecules with difficult recovery profiles. Careful extraction, clean-up, and chromatographic separation are not technical niceties; they determine whether the measured signal reflects biology or noise. In routine practice, small deviations in these steps can cascade into validation failures or uncertain sample interpretation.
Emerging Analytical Challenges Across New Therapeutic Modalities
The workshop scope extended well beyond traditional small-molecule assays. Discussions addressed deuterated drugs, lipid nanoparticle platforms, tumor and FFPE biopsy samples, targeted proteomics, small molecule covalent inhibitors, chiral bioanalysis, remote regulatory assessments, and sample reconciliation with chain of custody. Each of these topics brings a distinct analytical burden.
Deuterated drugs and covalent inhibitors demand careful consideration of structural stability and analyte specificity. Chiral bioanalysis requires attention to stereochemical resolution because enantiomers may behave differently in vivo and may not be interchangeable in assay readout. Targeted proteomics is increasingly relevant when protein biomarkers need reproducible quantitation across complex biological matrices. Tumor tissue and FFPE biopsy analysis add another layer of complexity because extraction efficiency, matrix effects, and specimen heterogeneity can all distort the measured result.
Lipid nanoparticle-based systems introduce still another problem: the bioanalytical target may not be a single molecule but a delivery construct whose components must be understood together. That makes assay design more than a measurement exercise; it becomes a question of whether the platform can faithfully represent what the therapy is doing in the body.
Regulated Bioanalysis and Biomarker Validation Demand Tighter Scientific Discipline
Part 1A of the white paper addresses regulated bioanalysis and biomarker validation, where the stakes are highest for reproducibility and regulatory acceptability. Bioanalysis in this setting is expected to support clinical development, comparative interpretation, and submission-grade evidence. Method validation therefore has to do more than document performance; it has to establish that the assay can withstand the demands of regulated use.
The paper also addresses biomarker, IVD, and companion diagnostic issues in the broader workshop ecosystem, even though those topics are expanded in later parts of the publication series. This framing matters because biomarker assays often sit at the boundary between exploratory science and decision-making tools. When a biomarker informs stratification, response assessment, or product characterization, analytical uncertainty can quickly become a clinical problem.
Immunogenicity, gene therapy, cell therapy, and vaccine programs were part of the larger workshop framework as well. Those areas impose distinctive assay expectations, often because the analytes are low-level, variable, or biologically dynamic. For that reason, the white paper’s recommendations are best read as a set of principles for disciplined assay control rather than a narrow method handbook.
A stable assay platform is only useful if sample identity and provenance are secure.
Regulatory Agency Input Gives the Workshop Its Practical Edge
The second half of this publication, Part 1B, gathers regulatory agency input on regulated bioanalysis and biomarker-related work. That inclusion is central to the value of the white paper. Bioanalytical scientists do not work in isolation; they operate within a framework shaped by agency expectations, inspection realities, and evolving interpretations of compliance.
Remote regulatory assessments were one of the special features of the 17th WRIB, and their presence in the white paper reflects how oversight has changed. Agencies now rely on remote access approaches in addition to on-site review, which raises practical questions about document readiness, data traceability, electronic systems, and the ability to demonstrate control over chain of custody. Laboratories that cannot show a coherent data trail can lose credibility even if the assay itself is technically sound.
The white paper’s discussion of sample reconciliation and chain of custody is therefore not administrative filler. In regulated bioanalysis, the chain connecting collection, transport, storage, preparation, and analysis is part of the assay itself. Breaks in that chain can invalidate the interpretation no matter how refined the analytical platform may be.
A Multi-Part Publication Reflects the Breadth of Current Bioanalytical Practice
Because the 2023 white paper is extensive, the publication has been divided into three parts. This first installment covers mass spectrometry assays, regulated bioanalysis and biomarker validation, and the regulatory inputs that informed the workshop. Part 2 covers biomarkers, IVD/companion diagnostics, ligand-binding assays, and cell-based assays, while Part 3 addresses gene therapy, cell therapy, vaccines, and biotherapeutic immunogenicity.
The publication structure mirrors the scale of current bioanalysis. No single assay format now captures the field’s demands, and no single regulatory template fits every therapeutic modality. The workshop’s recommendations aim to help laboratories and sponsors adapt their platforms to these changing requirements while preserving scientific excellence and regulatory compliance.
What remains unresolved is not whether bioanalysis matters, but how quickly the community can standardize expectations across increasingly diverse assay types and therapeutic products. The next parts of the white paper will extend that conversation into the biomarker, cell-based, and advanced therapy domains where assay complexity is highest and the margin for analytical error is narrowest.